Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CPN1 | P15169 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | EED | O75530 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21140619 | 0.98 | CYP1A2 (0.45) | CYP1A2HRH3HRH4KMT2ACPN1 | |
| SCHEMBL10346166 | 0.98 | CYP1A2 (0.45) | CYP1A2HRH3HRH4KMT2ACPN1 | |
| SCHEMBL17690276 | 0.93 | — | — | |
| SCHEMBL893581 | 0.93 | — | — | |
| Ammonia Solution, Strong SCHEMBL27321717 | 0.91 | HRH3 (0.44) | CYP1A2HRH3HRH4KMT2ACPN1 | |
| Hydrochloric Acid SCHEMBL31482227 | 0.91 | HRH3 (0.44) | CYP1A2HRH3HRH4KMT2ACPN1 | |
| Hydrochloric Acid SCHEMBL4428244 | 0.91 | HRH3 (0.44) | CYP1A2HRH3HRH4KMT2ACPN1 | |
| SCHEMBL16925545 | 0.86 | CYP1A2 (0.63) | CYP1A2HRH3HRH4KMT2ABACE1 | |
| Piperidine SCHEMBL28557465 | 0.84 | CYP1A2 (0.54) | CYP1A2CA1CA2CA4CHRNA7 | |
| SCHEMBL11633874 | 0.84 | CYP1A2 (0.50) | CYP1A2HRH3HRH4KMT2ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227314-B2 | Cystathionine-gamma-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170334866-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| WO-2017174621-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| EP-3153023-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | Intellikine, LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334866-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | CBS, CTH, BHMT | CYP1A2 3163/4885HRH3 3120/4885HRH4 3592/4885 |
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | CBS, CTH, BHMT | CYP1A2 3163/4885HRH3 3120/4885HRH4 3592/4885 |
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK6 | CYP1A2 4177/4885HRH3 1785/4885HRH4 2231/4885 |
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK5 | CYP1A2 3303/4885HRH3 1290/4885HRH4 2122/4885 |
| US-10227314-B2 | Cystathionine-gamma-lyase (CSE) inhibitors | CBS, CTH, BHMT | CYP1A2 3163/4885HRH3 3120/4885HRH4 3592/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CYP1A2 4815/4885HRH3 4198/4885HRH4 4698/4885 |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | PAK2, PAK3, PAK4 | CYP1A2 4769/4885HRH3 3614/4885HRH4 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.